Stock Track | Regenxbio Soars 6.47% Pre-market on Strong Q3 Results and Extended Cash Runway

Stock Track11-06

Regenxbio (NASDAQ: RGNX) stock surged 6.47% in pre-market trading following the release of its third-quarter 2025 financial results, which exceeded analyst expectations and demonstrated the company's improved financial position.

The biotechnology company reported Q3 earnings per share (EPS) of $(1.20), beating the estimated $(1.33). Revenue for the quarter came in at $29.733 million, surpassing the projected $24.125 million. This represents a 23% increase from the same period last year, driven by strong performance in license and royalty revenue, which reached $23.605 million.

Despite widening net losses to $61.941 million from $59.6 million year-over-year, investors were encouraged by Regenxbio's improved cash position. The company projects $302.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025, which is expected to fund operations into early 2027. This extended cash runway, coupled with better-than-expected financial results, has bolstered investor confidence in Regenxbio's long-term prospects and ability to advance its pipeline of gene therapy treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153318658?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153318658","market":"sg","top_or_hot":-1,"title":"Stock Track | Regenxbio Soars 6.47% Pre-market on Strong Q3 Results and Extended Cash Runway","media":"Stock Track","content":"<p>Regenxbio (NASDAQ: RGNX) stock surged 6.47% in pre-market trading following the release of its third-quarter 2025 financial results, which exceeded analyst expectations and demonstrated the company's improved financial position.</p>\n\n<p>The biotechnology company reported Q3 earnings per share (EPS) of $(1.20), beating the estimated $(1.33). Revenue for the quarter came in at $29.733 million, surpassing the projected $24.125 million. This represents a 23% increase from the same period last year, driven by strong performance in license and royalty revenue, which reached $23.605 million.</p>\n\n<p>Despite widening net losses to $61.941 million from $59.6 million year-over-year, investors were encouraged by Regenxbio's improved cash position. The company projects $302.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025, which is expected to fund operations into early 2027. This extended cash runway, coupled with better-than-expected financial results, has bolstered investor confidence in Regenxbio's long-term prospects and ability to advance its pipeline of gene therapy treatments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Regenxbio Soars 6.47% Pre-market on Strong Q3 Results and Extended Cash Runway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Regenxbio Soars 6.47% Pre-market on Strong Q3 Results and Extended Cash Runway\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Regenxbio (NASDAQ: RGNX) stock surged 6.47% in pre-market trading following the release of its third-quarter 2025 financial results, which exceeded analyst expectations and demonstrated the company's improved financial position.</p>\n\n<p>The biotechnology company reported Q3 earnings per share (EPS) of $(1.20), beating the estimated $(1.33). Revenue for the quarter came in at $29.733 million, surpassing the projected $24.125 million. This represents a 23% increase from the same period last year, driven by strong performance in license and royalty revenue, which reached $23.605 million.</p>\n\n<p>Despite widening net losses to $61.941 million from $59.6 million year-over-year, investors were encouraged by Regenxbio's improved cash position. The company projects $302.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025, which is expected to fund operations into early 2027. This extended cash runway, coupled with better-than-expected financial results, has bolstered investor confidence in Regenxbio's long-term prospects and ability to advance its pipeline of gene therapy treatments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGNX","symbol_name":"Regenxbio Inc","start_time":0,"source_url":"","article_id":"1153318658","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153318658","pubTimestamp":1762434265,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Regenxbio (NASDAQ: RGNX) stock surged 6.47% in pre-market trading following the release of its third-quarter 2025 financial results, which exceeded analyst expectations and demonstrated the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RGNX":"Regenxbio Inc"},"translate_title":"个股赛道|Regenxbio盘前大涨6.47%，Q3业绩强劲，现金跑道延长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGNX":1},"content_text":"Regenxbio (NASDAQ: RGNX) stock surged 6.47% in pre-market trading following the release of its third-quarter 2025 financial results, which exceeded analyst expectations and demonstrated the company's improved financial position.\nThe biotechnology company reported Q3 earnings per share (EPS) of $(1.20), beating the estimated $(1.33). Revenue for the quarter came in at $29.733 million, surpassing the projected $24.125 million. This represents a 23% increase from the same period last year, driven by strong performance in license and royalty revenue, which reached $23.605 million.\nDespite widening net losses to $61.941 million from $59.6 million year-over-year, investors were encouraged by Regenxbio's improved cash position. The company projects $302.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025, which is expected to fund operations into early 2027. This extended cash runway, coupled with better-than-expected financial results, has bolstered investor confidence in Regenxbio's long-term prospects and ability to advance its pipeline of gene therapy treatments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153318658","isCrawlerRequest":true}